Back

Composite impact of genome-wide APOBEC mutations and HLA haplotype on cancer immunogenicity has a sex-biased survival impact

Larijani, M.; Borzooee, F.; Heravi-Moussavi, A.

2024-08-08 cancer biology
10.1101/2024.08.07.607038 bioRxiv
Show abstract

APOBEC3A and APOBEC3B genome mutators drive tumor evolution and drug resistance but may also generate neoepitopes for cytotoxic T cells (CTL). Given the extensive polymorphism of Class I HLA, the CTL immunopeptidome, comprised of all 8-11mer peptides presented by an individuals six HLA class I alleles, varies person-to-person. We predicted the genome-wide impact of APOBEC3A/B-driven mutations on the immunogenicity of the immunopeptidomes of several thousand class I HLA alleles. Analysis of several billion APOBEC3-mediated mutations revealed that HLA class I alleles vary markedly in the susceptibility of their immunopeptidome to mutations. A subset of alleles of A1-A3 and B44 supertype supported increased neoepitopes. Notably, the immunogenicity changes supported by an individuals HLA class I alleles in response to APOBEC3 mutations predict survival in APOBEC3-mutated tumors and correlate with CTL activation. Thus, immunogenicity changes mediated by APOBEC3s impact survival, making HLA class I genotype a prognostic marker in APOBEC3-mutated tumors.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.